GuanfacineAlpha-2 adrenergic agonist
Guanfacine is a selective alpha-2A adrenergic agonist, first used to lower blood pressure, whose extended-release form (Intuniv) is approved for ADHD in children and adolescents, alone or added to a stimulant; Japan approved it for adults in 2019. In pediatric trials it reduced ADHD symptoms by a moderate amount, at the cost of sleepiness and lower blood pressure and pulse. Its reputation as a cognitive enhancer comes from monkey studies showing that it strengthens prefrontal working-memory circuits, but it did not improve memory or executive function in healthy young men or in healthy adults over 75.
Established